Home › Research › Health systems and care delivery
Clinical meaningfulness of anti-amyloid therapies in early Alzheimer's disease: Perspectives from the East and Southeast Asia region
Chen Christopher, Lee Jae-Hong, Park Kee Hyung, Hu Chaur-Jong, Mok Vincent, Senanarong Vorapun, Inaba Kaori, Dash Amitabh. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026-02-23
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive accumulation of toxic amyloid species. The rising prevalence of AD in Asia has made it an increasing public health concern, placing a substantial burden on the economy and healthcare systems. Anti-amyloid therapies (AATs) have demonstrated statistically significant slowing of disease progression at the group level in pivotal trials in early symptomatic AD. We explore the clinical meaningfulness of AATs and considerations impacting on its meaning in East and Southeast Asia. We acknowledge that there is a lack of data on Asian populations, particularly from the perspectives of patients and caregivers, highlighting the need for such evidence to facilitate the successful adoption of AATs in the region. We also propose the conceptual Connect, Align, Reframe, Explain (CARE) communication framework and practical tools to support effective communication with patients and caregivers regarding the benefits of AATs. HIGHLIGHTS: Anti-amyloid therapies (AATs) have demonstrated statistically significant group-level effects in slowing of disease progression in early symptomatic Alzheimer's disease. Translating clinical trial outcomes into measures of benefit that are truly meaningful to patients and caregivers is critical for the adoption of AATs. Asia, with its rapidly aging societies, diverse cultural norms and heterogeneous healthcare and reimbursement systems, presents a unique perspective on the clinical meaningfulness of AATs. The proposed Connect, Align, Reframe, Explain (CARE) communication framework concept and practical support tools, such as goal-setting checklist, visual aids and motivational messages, can facilitate effective communication with patients and caregivers regarding the benefit of AATs. Optimizing the full potential of AATs in Asia requires focused efforts on understanding patients' and caregivers' perspectives on treatment benefits, building regional registries to collect real-world data, and aligning care frameworks.
Key findings
- Anti-amyloid therapies (AATs) have demonstrated statistically significant slowing of disease progression at the group level in pivotal trials in early symptomatic AD.
- HIGHLIGHTS: Anti-amyloid therapies (AATs) have demonstrated statistically significant group-level effects in slowing of disease progression in early symptomatic Alzheimer's disease.
Why it matters
This paper discusses anti-amyloid therapies that have shown statistically significant group-level slowing of disease progression in early symptomatic Alzheimer's disease in pivotal trials. It notes a lack of data on Asian populations and highlights the need to translate trial outcomes into benefits that are meaningful to patients and caregivers.
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-17) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Amitabh Dash: h-index 13 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | National University of Singapore: institution h-index 1,167 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41724687) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Christopher, C., Jae-Hong, L., Hyung, P. K., Chaur-Jong, H., Vincent, M., Vorapun, S., et al. (2026). Clinical meaningfulness of anti-amyloid therapies in early Alzheimer's disease: Perspectives from the East and Southeast Asia region. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.71230
Vancouver
Christopher C, Jae-Hong L, Hyung PK, Chaur-Jong H, Vincent M, Vorapun S, et al. Clinical meaningfulness of anti-amyloid therapies in early Alzheimer's disease: Perspectives from the East and Southeast Asia region. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. doi:10.1002/alz.71230. PMID: 41724687.
BibTeX
@article{christopher2026-41724687,
author = {Christopher, Chen and Jae-Hong, Lee and Hyung, Park Kee and Chaur-Jong, Hu and Vincent, Mok and Vorapun, Senanarong and Kaori, Inaba and Amitabh, Dash},
title = {{Clinical meaningfulness of anti-amyloid therapies in early Alzheimer's disease: Perspectives from the East and Southeast Asia region}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2026},
doi = {10.1002/alz.71230},
pmid = {41724687},
url = {https://doi.org/10.1002/alz.71230}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Health systems and care delivery
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.